EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it will host a teleconference and webcast on Monday, April 27, 2009, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to provide an update on Nexavar(R) (sorafenib) tablets.
Interested parties may access a live webcast of the presentation on the company’s website at: http://www.onyx-pharm.com/wt/page/event_calendar or by dialing 847-413-3238 and using the passcode 24429530. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 24429530 approximately one hour after the teleconference concludes. The replay will be available through May 27, 2009.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(R). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company’s website at www.onyx-pharm.com.
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.
CONTACT: Alexandra Santos, +1-510-597-6504, for Onyx Pharmaceuticals, Inc.
Web site: http://www.onyx-pharm.com/
